BridgeBio Pharma Inc (NASDAQ:BBIO)
| 6.74 Delayed Data As of May 16 |  +0.12 / +1.81%Today’s Change | 4.98 Today|||52-Week Range 65.33 | -59.59% Year-to-Date |
| SECTOR Health Technology | INDUSTRY Biotechnology | MARKET CAP $977.0M |
Company Description
BridgeBio Pharma, Inc. engages in identifying and advancing transformative medicines to treat patients who suffer from Mendelian diseases. Its pipeline of development programs includes product candidates ranging from early discovery to late-stage development. The company was founded by Charles Homcy, Frank McCormick, Philip Reilly, and Neil Kumar in 2015 and is headquartered in Palo Alto, CA.
Contact Information
BridgeBio Pharma, Inc. 421 Kipling Street Palo Alto California 94301 |
Employees
Shareholders
| Individual stakeholders | 53.85% |
| Other institutional | 49.58% |
| Mutual fund holders | 22.36% |
Top Executives
| Neil Kumar | Chief Executive Officer & Director |
| Christine E. Siu | Chief Operating Officer |
| Brian C. Stephenson | Chief Financial Officer & Secretary |
| Uma Sinha | Chief Scientific Officer |
| Richard H. Scheller | Director, Chairman-Research & Development |
